Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Immucell ( (ICCC) ) just unveiled an update.
On January 8, 2026, ImmuCell reported preliminary, unaudited sales of $7.6 million for the fourth quarter of 2025, down 1.6% year on year, as domestic revenue grew 8.7% but international sales fell 52.6%. For full-year 2025, total sales rose 4.3% to $27.6 million, driven by a 26.5% jump in Tri-Shield First Defense sales and offset by a sharp decline in Dual-Force and other product sales, reflecting a customer shift within the First Defense portfolio and continued rebuilding of market position after earlier supply constraints. The company also disclosed that it expects to record approximately $3.6 million of non-cash impairment charges in the fourth quarter of 2025, including about $2.9 million tied to its paused Re-Tain program following an FDA Incomplete Letter issued on December 23, 2025, and additional write-downs of $0.1 million in other property, plant and equipment and $0.6 million of colostrum inventory no longer suitable for First Defense processing. Management plans to repurpose most of the roughly $15.5 million net book value of Re-Tain assets to expand First Defense manufacturing capacity, while continuing limited Re-Tain investigational work to attract partners, underscoring a strategic pivot toward scaling First Defense, boosting production efficiency, expanding the sales force and prioritizing higher-return uses of capital, with no material future cash outlays expected from the impairment charges.
The most recent analyst rating on (ICCC) stock is a Hold with a $5.50 price target. To see the full list of analyst forecasts on Immucell stock, see the ICCC Stock Forecast page.
Spark’s Take on ICCC Stock
According to Spark, TipRanks’ AI Analyst, ICCC is a Neutral.
Immucell’s overall stock score is driven by mixed financial performance and bearish technical indicators. The positive earnings call highlights improvements in net income and operational efficiency, but challenges in sales and inventory management persist. The valuation is reasonable, but the lack of a dividend yield limits its appeal.
To see Spark’s full report on ICCC stock, click here.
More about Immucell
ImmuCell Corporation (Nasdaq: ICCC) is an animal health company that develops, manufactures and markets products designed to improve cattle health and productivity, with a primary focus on its First Defense line, including Tri-Shield and Dual-Force formulations, sold to dairy and beef producers in domestic and international markets.
Average Trading Volume: 25,968
Technical Sentiment Signal: Buy
Current Market Cap: $57.44M
See more data about ICCC stock on TipRanks’ Stock Analysis page.